2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2323

Evaluation of Case-Finding Algorithms for Identification of Patients with Dermatomyositis
Abstract Number: 2324

Effects of 12 Weeks Low-Intensity Blood-Flow Restricted Resistance Training on Knee Extensor Strength in Patients with Sporadic Inclusion Body Myositis
Abstract Number: 2325

ANTI-Hmgcr Antibodies Demonstrate High Diagnostic VALUE in the Diagnosis of Immune Mediated Necrotizing Myopathy Following Statin Exposure
Abstract Number: 2326

Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease
Abstract Number: 2327

Cardiac Involvement in Inflammatory Myopathies: A Report from the Remicam Registry
Abstract Number: 2328

Serum Ferritin Levels, Distribution of Ground Glass Opacities and New Development of Lung Infiltration during Therapy Predict Prognosis of Interstitial Lung Disease in Anti-MDA5 Ab Positive Dermatomyositis
Abstract Number: 2329

Intravenous Immunoglobulins in the Treatment of Idiophatic Inflammatory Myopathies: Where Do We Stand?
Abstract Number: 2330

Ultrasound Imaging in Inclusion Body Myositis
Abstract Number: 2331

Trends in Joint Replacement Surgery in Patients with Rheumatoid Arthritis
Abstract Number: 2332

Midterm Outcome of Modular Metal-on-Metal Total Hip Arthroplasty
Abstract Number: 2333

Comparison of Clinical Outcomes of Total Ankle Arthroplasty Between Biologics and NON-Biologics Treatment Groups in Patients with Rheumatoid Arthritis
Abstract Number: 2334

Ultrasound-Guided Facet Joint Injections through a Longitudinal Approach
Abstract Number: 2335

Recent Changes of Radiological Findings and Patients’ Background of Rheumatoid Hip and Knee
Abstract Number: 2336

Splinting for Trigger Finger. Short Term Effects
Abstract Number: 2337

Sleep Quality, Disturbances and Physical Activity: A Nationwide Survey Among Health Professionals on Their Engagement with Irish People Who Have Rheumatic Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].